This retrospective analysis of a case-series of 14 patients presenting with SVT on the basis of underlying JAK2 V617F positive MPN was undertaken to examine these outcomes and response to real world therapy of this patient group. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.